CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Key Takeaways CDTX secured FDA Breakthrough Therapy designation for CD388 to prevent seasonal influenza.The FDA decision follows phase IIb data showing CD388's significant prevention of seasonal influenza.CDTX's ANCHOR phase III study began ahead of schedule and may support regulatory filing if successful.Cidara Therapeutics (CDTX) announced that the FDA has granted a Breakthrough Therapy designation to its lead pipeline candidate, CD388, for the prevention of seasonal influenza.Shares of the company were u ...